Reckitt At '2.0' On Nutrition Market Expansion But Question No. 1 Remains, Potential Pfizer Consumer Bid?
This article is powered by The Rose Sheet
Executive Summary
UK firm sees acquisitions of Mead Johnson Nutrition and the Schiff brand as major milestones in its trajectory as a consumer health market competitor, but market analysts say both would be rendered comparatively minor moves if it makes an offer to acquire Pfizer's consumer products business. Mead Johnson's Enfamil NeuroPro infant formula line extension formulated with "milk fat globule membrane" and DHA should be available in US in March or April.
You may also be interested in...
Infant Formula Production Stalls On Reckitt Benckiser's Latest Stumble
A "technical problem" interrupted infant formula production at firm's Netherlands plant during third quarter, causing a 8% dive in its revenues from Enfamil and other brand formulas. The problem has been corrected but revenues will be slowed during the current quarter and likely into early 2019. But analysts say the imapct could be deeper impact because it's the fourth problems since 2011 RB should have avoided.
Reckitt Ups 2018 Guidance On Mucinex 'All-In-One,' China Platform Gains
Max Cold & Flu All-In-One is the first Mucinex product providing an “all-in-one-and-done proposition" and is expected to offset the impact of private label products. Mucinex plus growth and expansion plans for infant formula spark increase in firm’s 2018 forecast.
Reckitt Ups 2018 Guidance On Mucinex 'All-In-One,' China Platform Gains
Max Cold & Flu All-In-One is the first Mucinex product providing an “all-in-one-and-done proposition" and is expected to offset the impact of private label products. Mucinex plus growth and expansion plans for infant formula spark increase in firm’s 2018 forecast.